Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af JNJ-78278343, et T-celle-omdirigerende middel rettet mod Human Kallikrein 2 (KLK2), for avanceret prostatakræft

2. november 2026 opdateret af: Janssen Research & Development, LLC

Et fase 1-studie af JNJ-78278343, et T-celle-omdirigerende middel rettet mod Human Kallikrein 2 (KLK2), for avanceret prostatakræft

The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

216

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forenede Stater, 10032
        • Columbia University Medical Center Herbert Irving Pavilion
    • Washington
      • Seattle, Washington, Forenede Stater, 98195-9472
        • University of Washington
      • Lyon, Frankrig, 69373
        • Centre Leon Berard
      • Marseille, Frankrig, 13005
        • APHM Hopital Timone
      • Villejuif, Frankrig, 94800
        • Institut Gustave Roussy
      • Amsterdam, Holland, 1066 CX
        • Antoni van Leeuwenhoek
      • Rotterdam, Holland, 3015 GD
        • Erasmus MC
      • Kashiwa, Japan, 277 8577
        • National Cancer Center Hospital East
      • Yokohama, Japan, 232 0024
        • Yokohama City University Medical Center
      • Beijing, Kina, 100191
        • Peking University Third Hospital
      • Chongqing, Kina, 400030
        • Chongqing University Cancer Hospital
      • Guangzhou, Kina, 510710
        • Sun Yat Sen University Cancer Center
      • Wenzhou, Kina, 325399
        • First Affiliated Hospital Of Wenzhou Medical College
      • Madrid, Spanien, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Madrid, Spanien, 28050
        • Hosp Univ Hm Sanchinarro
      • Málaga, Spanien, 29010
        • Hosp Virgen de La Victoria

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Confirmed adenocarcinoma of the prostate which has spread to other body parts
  • Part 1: Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
  • Measurable or evaluable disease
  • Concurrent use of any other anticancer treatment must be discontinued for at least 2 weeks before the first dose of study drug
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Prior surgical removal of testicles; or, for participants who have not undergone surgical removal of testicles, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog

Exclusion Criteria:

Disease conditions

  • Active central nervous system (CNS) involvement
  • Toxicity related to prior anticancer therapy has not adequately recovered

Prior/Concomitant Therapy

  • Prior treatment with human kallikrein (KLK) 2-targeted therapy
  • Received, or are receiving, medications that suppress the immune system within 3 days prior to the first dose of study drug
  • Received or plans to receive any live, attenuated vaccine within 4 weeks prior to the first dose of study drug

Prior/Concurrent Medical Conditions

  • Diagnosis of cancer other than prostate cancer within 2 years prior to the first dose of study drug
  • Solid organ or bone marrow transplantation
  • Major clotting diseases within one month prior to the first dose of study drug
  • Active autoimmune disease within 12 months prior to the first dose of study drug
  • Active infection
  • Major diseases of heart and blood vessels within 6 months prior to the first dose of study drug
  • Clinically significant lung diseases
  • Active or chronic hepatitis B or hepatitis C infection
  • Known positive test result for human immunodeficiency virus (unless stable on antiretroviral therapy with undetectable viral load)
  • Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: JNJ-78278343

Participants will receive JNJ-78278343. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 at recommended phase 2 dose (RP2D) as determined in Part 1. Participants who are still on study treatment (i.e., who are in Treatment Phase) at the time of the long term extension (LTE) will continue to receive study treatment until they reach a reason for discontinuation of treatment or until further notification by the sponsor of a different means for continued supply of study treatment, whichever occurs first.

JNJ-78278343 will be administered.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1 and 2: Number of Participants With Adverse Events (AEs)
Tidsramme: Up to 1 year and 10 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Up to 1 year and 10 months
Part 1 and 2: Number of Participants With AEs by Severity
Tidsramme: Up to 1 year and 10 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.

Up to 1 year and 10 months
Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Tidsramme: Up to 1 year and 10 months

Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 1 year and 10 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serum Concentration of JNJ-78278343
Tidsramme: Up to 1 year and 10 months

Serum concentrations of JNJ-78278343 will be determined.

Up to 1 year and 10 months
Systemic Cytokine Concentrations
Tidsramme: Up to 1 year and 10 months

Cytokine concentrations will be determined for biomarker assessment.

Up to 1 year and 10 months
Serum Prostate Specific Antigen (PSA) Concentration
Tidsramme: Up to 1 year and 10 months

Serum PSA concentration will be measured.

Up to 1 year and 10 months
Number of Participants With Anti-JNJ-78278343 Antibodies
Tidsramme: Up to 1 year and 10 months

Serum samples will be analyzed for the detection of anti-JNJ-78278343 antibodies using a validated assay method.

Up to 1 year and 10 months
Objective Response Rate (ORR)
Tidsramme: Up to 1 year and 10 months

ORR is defined as the percentage of participants who have a partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version 1.1 response criteria without evidence of bone progression according to prostate cancer working group 3 (PCWG3).

Up to 1 year and 10 months
Radiographic Progression-free Survival (rPFS)
Tidsramme: Up to 1 year and 10 months

rPFS is defined as time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first.

Up to 1 year and 10 months
PSA Response Rate
Tidsramme: Up to 1 year and 10 months

PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline. The maximum reduction from baseline in PSA will also be calculated during the treatment.

Up to 1 year and 10 months
Duration of Response (DOR)
Tidsramme: Up to 1 year and 10 months

DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.

Up to 1 year and 10 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. juli 2021

Primær færdiggørelse (Anslået)

31. marts 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

20. maj 2021

Først indsendt, der opfyldte QC-kriterier

20. maj 2021

Først opslået (Faktiske)

24. maj 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CR108958
  • 2020-005970-83 (EudraCT nummer)
  • 78278343PCR1001 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-506585-31-00 (Registry Identifier: EUCT number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner